Comparative Pharmacology
Head-to-head clinical analysis: COUMADIN versus HEPARIN SODIUM 25 000 UNITS AND DEXTROSE 5 IN PLASTIC CONTAINER.
Peer-Reviewed Evidence
Head-to-head clinical analysis: COUMADIN versus HEPARIN SODIUM 25 000 UNITS AND DEXTROSE 5 IN PLASTIC CONTAINER.
COUMADIN vs HEPARIN SODIUM 25,000 UNITS AND DEXTROSE 5% IN PLASTIC CONTAINER
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Inhibits vitamin K epoxide reductase complex 1 (VKORC1), thereby decreasing the synthesis of vitamin K-dependent clotting factors II, VII, IX, and X, as well as anticoagulant proteins C and S.
Heparin binds to antithrombin III, causing a conformational change that accelerates the inactivation of thrombin (factor IIa) and factor Xa. This inhibits fibrin formation and prevents clot propagation. Dextrose 5% provides a source of calories and fluid.
Initial dose 2-5 mg orally once daily, adjusted based on INR response; typical maintenance dose 2-10 mg/day.
For therapeutic anticoagulation in adults, heparin is administered intravenously as an initial bolus of 80 units/kg followed by a continuous infusion of 18 units/kg/hour, with dose adjustment based on activated partial thromboplastin time (aPTT) targeting 1.5-2.5 times control. The concentration of heparin sodium 25,000 units and dextrose 5% in plastic container is typically used for continuous infusion at a rate calculated to deliver the prescribed units per hour.
None Documented
None Documented
Terminal elimination half-life: 20–60 hours (mean ~40 hours); clinically, anticoagulant effect persists for 2–5 days after stopping due to hepatic synthesis of functional clotting factors.
Terminal elimination half-life: 1-2 hours (dose-dependent, prolonged with higher doses due to saturable clearance). In hepatic or renal impairment: 1.5-3 hours. Clinical context: Twice-daily dosing may not maintain therapeutic levels; monitoring aPTT is essential.
Renal (approximately 92% as inactive metabolites), fecal/biliary (minor, approximately 8%). Less than 2% excreted unchanged.
Renal: 40-50% as unchanged heparin (saturable); reticuloendothelial system: partial metabolism to uroheparin (less active); fecal: minimal (<5%).
Category C
Category A/B
Anticoagulant
Anticoagulant